ElvaBio

EvlaBio

EvlaBio develops monoclonal antibody therapeutics for patients with chronic kidney disease to treat left ventricular hypertrophy by targeting the FGFR4/FGF23 signalling axis.

SenyaTx

This company develops antibody-based therapeutics targeting the LRG1 protein to treat patients with chronic vascular diseases, including nephrology, oncology, and ophthalmology conditions.

Braveheart Bio

This biopharmaceutical company develops small-molecule therapeutics to treat patients with hypertrophic cardiomyopathy and other serious cardiovascular conditions.

Corvidia Therapeutics

This clinical-stage biotechnology company develops precision therapies for patients with chronic kidney disease who are at high risk of cardiovascular events.

Staten Biotechnology

This company develops monoclonal antibody therapies for patients with dyslipidaemia to reduce cardiovascular risk and lower triglyceride levels.

Calluna Pharma

This clinical-stage company develops monoclonal antibodies to treat inflammatory and fibrotic diseases for patients with conditions like idiopathic pulmonary fibrosis and chronic kidney disease.

BYOMass

This company develops biologic and small molecule drugs targeting the TGF-beta superfamily to treat metabolic, fibrotic and age-related diseases for patients with unmet needs.

Ethyreal Bio

This company develops monoclonal antibodies to treat Graves' disease and thyroid eye disease for patients with these autoimmune conditions.